Comorbid diseases and the structure of mortality in patients with a new coronavirus infection

The aim of this work was to study the risk factors for severe COVID-19, comorbid diseases, and the structure of mortality in patients who died in a hospital from a new coronavirus infection. The study included 180 patients with bilateral viral polysegmental pneumonia caused by SARS-CoV-2. In patients with viral pneumonia, the degree of lung tissue damage, the frequency and severity of comorbid diseases were studied: arterial hypertension, coronary heart disease, cerebrovascular diseases (chronic cerebral ischemia, cerebral stroke), atrial fibrillation, chronic heart failure, chronic kidney disease, diabetes mellitus type 2, obesity, malignancy and anemia. In patients with COVID-19-associated pneumonia, severe lung damage was observed – pneumonia with CT3 (36.1%) and CT4 (33.0%) prevailed, less often CT2 (30.9%). A high frequency of comorbid diseases was found in deceased patients with viral pneumonia: arterial hypertension (98.9%), cerebrovascular disease (96.9%), coronary heart disease (83.9%), chronic kidney disease (96.7%), type 2 diabetes mellitus and atrial fibrillation – in almost half of patients (42.2%), and in every third patient – obesity (36.6%). The main causes of death in patients with COVID-19-associated pneumonia were: acute respiratory distress syndrome (83.3%), less often acute myocardial infarction (7.2%), cerebral infarction and edema (5.6%), thromboembolism pulmonary artery (3.9%). In patients with viral pneumonia caused by SARS-CoV-2, there is a high frequency of comorbid conditions leading to a severe course of the disease: arterial hypertension, coronary heart disease, severe chronic heart failure, advanced age (> 75 years), lack of vaccination, chronic kidney disease, obesity of the 3rd degree, diabetes mellitus type 2. Among women who died from COVID-19-associated pneumonia, such risk factors as age over 75 years, type 2 diabetes, lack of vaccination, a history of myocardial infarction with the development of chronic heart failure stages 2A and 2B, and chronic microcytic anemia prevailed; among the dead men – obesity of the third degree, a history of cerebral stroke, lack of vaccination and severe chronic heart failure.

1. Interim guidelines «Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)». Version 15 (22.02.22).

2. Vertkin A. L., Zayrat#yants O. V. Approaches to the treatment of COVID-19 from the standpoint of correction of endotheliopathy and prevention of thrombotic complications // Meditsinskiy alfavit. 2021; 7: 46-50.

3. Sycheva A. S., Kebina A. L., Vërtkin A. L. Clinical and prognostic criteria for the complicated course of a new coronavirus infection (COVID-19) // Mediko-farmatsevticheskiy zhurnal Pul}s. 2021; 9 (23): 147-153.